Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Laura Räisänen, Fariha Balouch, Claire Reilly, Christopher Burgess, Peter Lewindon
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867018595328851968
author Laura Räisänen
Fariha Balouch
Claire Reilly
Christopher Burgess
Peter Lewindon
author_facet Laura Räisänen
Fariha Balouch
Claire Reilly
Christopher Burgess
Peter Lewindon
Laura Räisänen
Fariha Balouch
Claire Reilly
Christopher Burgess
Peter Lewindon
collection Wiley Open Access
contents Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis Laura Räisänen Fariha Balouch Claire Reilly Christopher Burgess Peter Lewindon British Journal of Clinical Pharmacology AimsAtypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy. We compared oral vancomycin solution to capsules in inducing remission in children with atypical colitis, while assessing other potential confounders.MethodsChildren using oral vancomycin for at least 3 months to manage atypical colitis were retrospectively identified. Factors associated with colitis remission (Paediatric Ulcerative Colitis Activity Index [PUCAI], faecal calprotectin, colonoscopy and histology) were explored.ResultsOf 32/48 children with elevated PUCAI, 27/32 achieved PUCAI < 10 (20/23 after solution vs. 7/9 after capsules, P = .520). Faecal calprotectin <100 μg/g was achieved in 35/48 (28/35 after solution vs. 6/13 after capsules, P = .022). Follow‐up colonoscopy during treatment (n = 25) showed reduced Mayo from median 2 to 0 (P < .001) after solution vs. from 2 to 1 (P = .257) after capsules. Pan‐colonic histological remission was seen in 14/25 (12/20 after solution vs. 1/5 after capsules, P = .109). In adjusted analysis, use of oral vancomycin solution was a significant predictor for biomarker (adjusted odds ratio 23.1, 95% confidence interval 2.11–253) and pan‐colonic histological remission (adjusted odds ratio 900, 95% confidence interval 1.61–504 929). No other predictors were identified. Within 12 months after ceasing oral vancomycin in children who achieved remission, 52% relapsed. No clinical predictors, including vancomycin preparation, were established.ConclusionOral vancomycin solution was superior to capsules for inducing biomarker and colonoscopic remission in children with atypical colitis with/without confirmed PSC. This finding warrants further investigation to ensure optimal use. 10.1002/bcp.70121 http://creativecommons.org/licenses/by-nc-nd/4.0/
doi_str_mv 10.1002/bcp.70121
format Artículo Open Access
id wiley_oa_10_1002_bcp_70121
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis
Laura Räisänen
Fariha Balouch
Claire Reilly
Christopher Burgess
Peter Lewindon
British Journal of Clinical Pharmacology
Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis Laura Räisänen Fariha Balouch Claire Reilly Christopher Burgess Peter Lewindon British Journal of Clinical Pharmacology AimsAtypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy. We compared oral vancomycin solution to capsules in inducing remission in children with atypical colitis, while assessing other potential confounders.MethodsChildren using oral vancomycin for at least 3 months to manage atypical colitis were retrospectively identified. Factors associated with colitis remission (Paediatric Ulcerative Colitis Activity Index [PUCAI], faecal calprotectin, colonoscopy and histology) were explored.ResultsOf 32/48 children with elevated PUCAI, 27/32 achieved PUCAI < 10 (20/23 after solution vs. 7/9 after capsules, P = .520). Faecal calprotectin <100 μg/g was achieved in 35/48 (28/35 after solution vs. 6/13 after capsules, P = .022). Follow‐up colonoscopy during treatment (n = 25) showed reduced Mayo from median 2 to 0 (P < .001) after solution vs. from 2 to 1 (P = .257) after capsules. Pan‐colonic histological remission was seen in 14/25 (12/20 after solution vs. 1/5 after capsules, P = .109). In adjusted analysis, use of oral vancomycin solution was a significant predictor for biomarker (adjusted odds ratio 23.1, 95% confidence interval 2.11–253) and pan‐colonic histological remission (adjusted odds ratio 900, 95% confidence interval 1.61–504 929). No other predictors were identified. Within 12 months after ceasing oral vancomycin in children who achieved remission, 52% relapsed. No clinical predictors, including vancomycin preparation, were established.ConclusionOral vancomycin solution was superior to capsules for inducing biomarker and colonoscopic remission in children with atypical colitis with/without confirmed PSC. This finding warrants further investigation to ensure optimal use. 10.1002/bcp.70121 http://creativecommons.org/licenses/by-nc-nd/4.0/
title Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis
topic British Journal of Clinical Pharmacology
url https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70121